Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants and are considered to have treatment-resistant depression. Methods: This Phase 3, double-blind, multicenter study enrolled adults with moderate-to-severe depression and nonresponse to ≥2 antidepressants in the current depression episode. Eligible patients (N = 346) were randomized (1:1:1) to twice-weekly nasal spray treatment (esketamine [56 or 84 mg] or placebo) plus a newly initiated, open-label, oral antidepressant taken daily for 4 weeks. The primary efficacy endpoint was change from baseline to day 28 in the Montgomery-Asberg Depression Rating Scale total score, performed by blinded, remote raters. Based on the predefined statistical testing sequence, esketamine 84 mg/antidepressant had to be significant for esketamine 56 mg/antidepressant to be formally tested. Results: Statistical significance was not achieved with esketamine 84 mg/antidepressant compared with antidepressant/placebo (least squares [LS] means difference [95% CI]: –3.2 [–6.88, 0.45]; 2-sided P value = .088). Although esketamine 56 mg/antidepressant could not be formally tested, the LS means difference was –4.1 [–7.67, –0.49] (nominal 2-sided P value = .027). The most common (>20%) adverse events reported for esketamine/antidepressant were nausea, dissociation, dizziness, vertigo, and headache. Conclusions: Statistical significance was not achieved for the primary endpoint; nevertheless, the treatment effect (Montgomery-Asberg Depression Rating Scale) for both esketamine/antidepressant groups exceeded what has been considered clinically meaningful for approved antidepressants vs placebo. Safety was similar between esketamine/antidepressant groups and no new dose-related safety concerns were identified. This study provides supportive evidence for the safety and efficacy of esketamine nasal spray as a new, rapid-acting antidepressant for patients with treatment-resistant depression. Trial Registration: ClinicalTrials.gov identifier: NCT02417064
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least squares mean change (±SE) in Montgomery-Asberg Depression Rating Scale (MADRS) total score over time in double-blind phase (observed cases mixed model for repeated measures [MMRM]). LS, least squares; SE, standard error. LS mean and SE were based on MMRM with change from baseline as the response variable and the fixed effect model terms for treatment (esketamine 56 mg/antidepressant, esketamine 84 mg/antidepressant, antidepressant/placebo), day, region, class of oral antidepressant, and treatment-by-day, and baseline value as a covariate. Results are not adjusted for multiple comparisons or sample size reestimation. Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/2c4f045dfb03494db68f2585854e303a/efficacy-and-safety-of-fixed-dose-esketamine-nasal-spray-combined-with-a-new-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Fedgchin’s group conducted an analogous study, which did not support adjunctive esketamine’s AD efficacy for TRD [111].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [111]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials found that esketamine, in combination with an oral antidepressant, rapidly reduced suicidal thoughts compared to placebo in adults with TRD who were at imminent risk for suicide [65,88,89].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In one of those (NCT02417064 [9]), statistical significance should not have been tested for the 56 mg treatment group due to the hierarchical analysis and the absence of a significant difference in the 84 mg group tested first.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, when reviewing the major esketamine trials, significantly increased rates of somnolence versus placebo have been reported, especially in relapse-prevention studies,74,152 but this has not been seen consistently.153”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [152]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because this was statistically tested when it should not have been, it introduced some spin into the published report [9], despite the numerical results being deemed reproducible.”
From Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials (2025) · cites this paper as [9]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Spitzer, R. L. (1999) · JAMA · doi:10.1001/jama.282.18.1737 · Cited by 9,802
(1976) · Medical Entomology and Zoology · Cited by 8,899
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“In patients who respond to biogenic amine antidepressants, the time to onset of effect is typically 3 to 7 weeks, during which time patients remain symptomatic and at risk of self-harm (Rush et al., 2006).”
BackgroundSelf-citationDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 5×
“About one-third of patients with MDD fail to achieve remission despite treatment with multiple biogenic amine (e.g., serotonin, norepinephrine) antidepressants and hence have treatment-resistant depression (TRD) (Fava, 2003).”
BackgroundMethodInfluentialSelf-citationKennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Self-citationPosner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Cited by
Items 101–200 of 679
Guo, H., Wang, B., Yuan, S., Wu, S., Liu, J., He, M., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.849758 · Cited by 38
Intranasal esketamine: From origins to future implications in treatment-resistant depression
Sanders, B. J., & Brula, A. Q. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.020 · Cited by 38
Jawad, M. Y., Vincenzo, J. D. D., Ceban, F., Jaberi, S., Lui, L. M. W., Gillissie, E. S., Alnefeesi, Y., Rosenblat, J. D., & McIntyre, R. S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2058488 · Cited by 37
Borentain, S., Gogate, J. P., Williamson, D., Carmody, T. J., Trivedi, M. H., Jamieson, C., Cabrera, P., Popova, V., Wajs, E., DiBernardo, A., et al. (2022) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1927 · Cited by 37
Self-citationThe therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
Jawad, M. Y., Vincenzo, J. D. D., Badulescu, S., Teopiz, K. M., Tabassum, A., Ceban, F., Mckenzie, A., Meshkat, S., Rosenblat, J. D., Ho, R., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109299 · Cited by 36
Chen, X., Hou, X., Bai, D., Lane, R., Zhang, C., Canuso, C., Wang, G., & Fu, D.-J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s391096 · Cited by 35
“There were no obvious factors identified to explain the difference in the primary efficacy outcome between China and US subgroups, and global phase 3 TRD studies.(17,33) With respect to PK, esketamine concentrations exhibited the expected dose-dependent differences between the 56 mg and 84 mg doses and were similar to…”
ResultSelf-citationKetamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
Ragnhildstveit, A., Slayton, M., Jackson, L. K., Brendle, M., Ahuja, S., Holle, W., Moore, C., Sollars, K., Seli, P., & Robison, R. (2022) · Brain Sciences · doi:10.3390/brainsci12030382 · Cited by 35
Fang, S., Yang, X., & Zhang, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1359088 · Cited by 36
Saad, Z. S., Hibar, D. P., Fedgchin, M. M., Popova, V., Furey, M. L., Singh, J. B., Kolb, H. C., Drevets, W. C., & Chen, G. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa030 · Cited by 35
Self-citationJones, R., Freeman, M. P., Kornstein, S. G., Cooper, K., Daly, E., Canuso, C. M., & Nicholson, S. (2022) · Archives of Women s Mental Health · doi:10.1007/s00737-021-01185-6 · Cited by 34
Self-citation(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders
Shafique, H. S., Demers, J. C., Biesiada, J., Golani, L. K., Cerne, R., Smith, J. L., Szostak, M., & Witkin, J. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126804 · Cited by 34
Terao, I., Tsuge, T., Endo, K., & Kodama, W. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.11.023 · Cited by 33
Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis
Hieronymus, F., López, E., Sjögren, H. W., & Lundberg, J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.24119 · Cited by 34
Vankawala, J., Naples, G., Avila-Quintero, V. J., Ramírez, K. L., Flores, J. M., Bloch, M. H., & Dwyer, J. B. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.549080 · Cited by 33
Managing dissociative symptoms following the use of esketamine nasal spray: a case report
Pereira, S., Brennan, E. A., Patel, A. B., Moran, M., Wallier, J., & Liebowitz, M. R. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000327 · Cited by 33
Self-citationOkada, M., Kawano, Y., Fukuyama, K., Motomura, E., & Shiroyama, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217951 · Cited by 32
Yang, S., Wang, J., Li, X., Wang, T., Xu, Z., Xu, X. M., Zhou, X., & Chen, G. (2021) · Psychiatric Quarterly · doi:10.1007/s11126-020-09871-x · Cited by 32
Halaris, A. E., & Cook, J. T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_21 · Cited by 33
Boudieu, L., Mennetrier, M., Llorca, P., & Samalin, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122773 · Cited by 32
Registered clinical trials investigating ketamine for psychiatric disorders
Peyrovian, B., McIntyre, R. S., Phan, L., Lui, L. M. W., Gill, H., Majeed, A., Chen-Li, D., Nasri, F., & Rosenblat, J. D. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.03.020 · Cited by 27
Drevets, W. C., Bhattacharya, A., & Furey, M. L. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.04.002 · Cited by 30
Self-citationTelepsychiatry: The future is already present
Gutiérrez-Rojas, L., Álvarez-Mon, M. Á., Andreu-Bernabeu, Á., Capitán, L., Cuevas, C. D. L., Gómez, J. C., Grande, I., Hidalgo‐Mazzei, D., Mateos, R., Moreno-Gea, P., et al. (2022) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2022.09.001 · Cited by 30
Jamieson, C., Popova, V., Daly, E., Cooper, K., Drevets, W. C., Rozjabek, H., & Singh, J. B. (2023) · Health and Quality of Life Outcomes · doi:10.1186/s12955-023-02113-1 · Cited by 30
Self-citationGałecki, P., & Bliźniewska-Kowalska, K. M. (2019) · Psychiatria Polska · doi:10.12740/pp/onlinefirst/115208 · Cited by 30
Citrome, L., DiBernardo, A., & Singh, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.106 · Cited by 26
Self-citationBorentain, S., Williamson, D., Turkoz, I., Popova, V., McCall, W. V., Mathews, M., & Wiegand, F. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s339090 · Cited by 29
The antidepressant effect and safety of non-intranasal esketamine: A systematic review
Smith-Apeldoorn, S. Y., Vischjager, M., Veraart, J. K. E., Kamphuis, J., Rot, M. A. H., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221084055 · Cited by 29
Ingrosso, G., Cleare, A. J., & Juruena, M. F. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303597 · Cited by 28
Doty, R. L., Popova, V., Wylie, C., Fedgchin, M. M., Daly, E., Janik, A., Ochs-Ross, R., Lane, R., Lim, P., Cooper, K. L., et al. (2021) · CNS Drugs · doi:10.1007/s40263-021-00826-9 · Cited by 28
Self-citationLe, T. T., Vincenzo, J. D. D., Teopiz, K. M., Lee, Y. L., Cha, D. S., Lui, L. M. W., Rodrigues, N. B., Ho, R., Cao, B., Lin, K., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114231 · Cited by 28
Kumari, S., Chaudhry, H. A., Sagot, A. J., Doumas, S. J., Abdullah, H. M., Alcera, E. C., Solhkhah, R., & Afzal, S. (2024) · Cureus · doi:10.7759/cureus.53987 · Cited by 28
Jeon, H. J., Ju, P., Sulaiman, A. H., Aziz, S. A., Paik, J., Tan, W., Bai, D., & Li, C. (2022) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2022.20.1.70 · Cited by 27
Dai, D., Miller, C., Valdivia, V., Boyle, B. W., Bolton, P., Li, S., Seiner, S. J., & Meisner, R. C. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03789-3 · Cited by 27
Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression
Zavaliangos‐Petropulu, A., McClintock, S. M., Khalil, J., Joshi, S. H., Taraku, B., Al‐Sharif, N., Espinoza, R. T., & Narr, K. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.015 · Cited by 27
Role of Ketamine in the Treatment of Psychiatric Disorders
Derakhshanian, S., Zhou, M., Rath, A., Barlow, R., Bertrand, S. C., DeGraw, C., Lee, C., Hasoon, J. J., & Kaye, A. D. (2021) · Health Psychology Research · doi:10.52965/001c.25091 · Cited by 27
Kratter, I. H., Austelle, C. W., Lissemore, J. I., Wada, M., Geoly, A. D., Chaiken, A., Kaloiani, I., Johnson, N. D., Wan, S., Kozyr, L., et al. (2026) · World Psychiatry · doi:10.1002/wps.70032 · Cited by 27
Increased use of ketamine for the treatment of depression: Benefits and concerns
Na, K., & Kim, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110060 · Cited by 26
An update on antidepressant pharmacotherapy in late-life depression
Brender, R., Mulsant, B. H., & Blumberger, D. M. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1921736 · Cited by 26
Nikayin, S., & Sanacora, G. (2021) · CNS Drugs · doi:10.1007/s40263-021-00851-8 · Cited by 26
Baudot, J., Soeiro, T., Tambon, M., Navarro, N., Veyrac, G., Mezaache, S., & Micallef, J. (2021) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12745 · Cited by 26
Wong, S., Kwan, A. T. H., Teopiz, K. M., Le, G. H., Meshkat, S., Ho, R., d’Andrea, G., Cao, B., Vincenzo, J. D. D., Rosenblat, J. D., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.142 · Cited by 26
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data
Nijs, M., Wajs, E., Aluisio, L. E., Turkoz, I., Daly, E., Janik, A., Borentain, S., Singh, J. B., DiBernardo, A., & Wiegand, F. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa027 · Cited by 26
Self-citationThe Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 25
Włodarczyk, A., Cubała, W. J., Gałuszko‐Węgielnik, M., & Szarmach, J. (2021) · Medicine · doi:10.1097/md.0000000000026769 · Cited by 25
Turkoz, I., Nelson, J. C., Wilkinson, S. T., Borentain, S., Macaluso, M., Trivedi, M. H., Williamson, D., Sheehan, J. J., Salvadore, G., Singh, J. B., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115165 · Cited by 25
Self-citationTurkoz, I., Daly, E., Singh, J. B., Lin, X., Tymofyeyev, Y., Williamson, D., Salvadore, G., Nash, A. I., Macaluso, M., Wilkinson, S. T., et al. (2021) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20m13800 · Cited by 25
Self-citationMorrens, J., Mathews, M., Popova, V., Borentain, S., Rive, B., Gonzalez Martin Moro, B., Jamieson, C., & Zhang, Q. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s358367 · Cited by 24
Hack, L. M., Zhang, X., Heifets, B. D., Suppes, T. M., van Roessel, P., Yesavage, J. A., Gray, N. J., Hilton, R. A., Bertrand, C., Rodríguez, C. I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42141-5 · Cited by 24
Overcoming the myths of esketamine administration: different and not difficult
Buchmayer, F., & Kasper, S. F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1279657 · Cited by 25
Dahan, J. D. C., Dadiomov, D., Bostoen, T., & Dahan, A. (2024) · npj Mental Health Research · doi:10.1038/s44184-024-00091-w · Cited by 25
Esketamine combined with SSRI or SNRI for treatment-resistant depression
Del Casale, A., Spirito, S., Arena, J. F., Preissner, S., Borro, M., Gentile, G., Modesti, M. N., Preissner, R., Ferracuti, S., & Simmaco, M. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0200 · Cited by 23
Jha, M. K., Williamson, D., Magharehabed, G., Turkoz, I., Daly, E., & Trivedi, M. H. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.10.020 · Cited by 23
Self-citationA link between ghrelin and major depressive disorder: a mini review
Lis, M., Miłuch, T., Majdowski, M., & Zawodny, T. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1367523 · Cited by 23
Pardossi, S., Fagiolini, A. M., Scheggi, S., & Cuomo, A. (2024) · Children · doi:10.3390/children11070801 · Cited by 23
Esketamine in depression: putative biomarkers from clinical research
Johnston, J. N., Zarate, C. A., & Kvarta, M. D. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01865-1 · Cited by 23
Ludwig, V. M., Sauer, C., Young, A. H., Rucker, J., Bauer, M., Findeis, H., & Ritter, P. S. (2021) · CNS Drugs · doi:10.1007/s40263-021-00837-6 · Cited by 23
Kritzer, M. D., Pae, C., & Masand, P. S. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2069749 · Cited by 23
ERK/mTOR signaling may underlying the antidepressant actions of rapastinel in mice
Shen, M., Lv, D., Liu, X., & Wang, C. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-02290-5 · Cited by 22
Samalin, L., Mékaoui, L., Rothärmel, M., Sauvaget, A., Wicart, C., Dupin, J., Cohignac, V., & Gaudre-Wattinne, E. (2024) · Depression and Anxiety · doi:10.1155/2024/7262794 · Cited by 22
Gibuła‐Tarłowska, E., Wiszniewska, A., Turyk, M., Szymczyk, P., Kotlinska, J. H., & Kędzierska, E. (2025) · Molecules · doi:10.3390/molecules30132824 · Cited by 22
Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review
Orsini, D. K., Wong, S., Luch, S. D. D., Chan, B., Vasudeva, S., Lovell, G. F. M., Le, G. H., Jones, B. D. M., Chisamore, N., Mollica, A., et al. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2026.0255 · Cited by 22
Levinta, A., Meshkat, S., McIntyre, R. S., Ho, C., Lui, L. M. W., Lee, Y. L., Mansur, R. B., Teopiz, K. M., Rodrigues, N. B., Vincenzo, J. D. D., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.08.050 · Cited by 22
Oraee, S., Alinejadfard, M., Golsorkh, H., Sadeghian, M., Fanaei, M., Centis, R., D’Ambrosio, L., Sotgiu, G., Goudarzi, H., Migliori, G. B., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.11.010 · Cited by 22
Floden, L. L., Hudgens, S. A., Jamieson, C., Popova, V., Drevets, W. C., Cooper, K., & Singh, J. B. (2022) · CNS Drugs · doi:10.1007/s40263-022-00916-2 · Cited by 22
Self-citationA systematic review of ketamine for the treatment of depression among older adults
Gupta, A., Dhar, R., Patadia, P., Funaro, M. C., Bhattacharya, G., Farheen, S. A., & Tampi, R. R. (2020) · International Psychogeriatrics · doi:10.1017/s1041610220000903 · Cited by 22
Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention—Mechanisms and Pharmacodynamics
Song, H., Luo, Y., & Fang, L. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s486118 · Cited by 21
Clinical overview of NMDA-R antagonists and clinical practice
Davoudian, P. A., & Wilkinson, S. T. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.04.004 · Cited by 21
Tsang, V. W. L., Tao, B. K.-L., Dames, S., Walsh, Z., & Kryskow, P. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231171512 · Cited by 21
Intranasal esketamine: A novel drug for treatment-resistant depression
Khorassani, F., & Talreja, O. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa191 · Cited by 21
Repeated Dosing of Ketamine in the Forced Swim Test: Are Multiple Shots Better Than One?
Weston, R., Fitzgerald, P. J., & Watson, B. O. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.659052 · Cited by 21
Liu, P., Zhang, S., Liang, Y., Gao, Z., Gao, W., & Dong, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s388764 · Cited by 21
Singh, J. B., Fedgchin, M. M., Daly, E., & Drevets, W. C. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.05.002 · Cited by 20
Self-citationDevelopment of a patient decision aid for treatment resistant depression
Shillington, A. C., Langenecker, S. A., Shelton, R. C., Foxworth, P. M., Allen, L. G., Rhodes, M., Pesa, J. A., Williamson, D., & Holmes-Rovner, M. M. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.014 · Cited by 20
Hecking, J., Davoudian, P. A., & Wilkinson, S. T. (2021) · Chronic Stress · doi:10.1177/24705470211020446 · Cited by 20
Maldi, K. D., Asellus, P., Myléus, A., & Norström, F. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03601-8 · Cited by 20
Esketamine: A Drug to Treat Resistant Depression That Brings More Questions Than Answers
Mischel, N., & Balon, R. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001395 · Cited by 20
Zhou, Y., Wang, C., Lan, X., Zheng, W., Li, H., Chao, Z., McIntyre, R. S., & Ning, Y. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.032 · Cited by 19
Martiadis, V., Raffone, F., Testa, S., Iaccarino, C., Giunnelli, P., Orrico, A., Carbone, E., Clemente, S., Simone, C. D., Massa, A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041629 · Cited by 19
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
Early effects predict trajectories of response to esketamine in treatment-resistant depression
Estrade, I., Petit, A., Sylvestre, V., Danon, M., Leroy, S., Perrain, R., Vinckier, F., Mékaoui, L., Gaillard, R., Advenier-Iakovlev, E., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.09.030 · Cited by 19
Self-citationIs there a risk of esketamine misuse in clinical practice?
Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 18
Metabolic Risk Factors and Cardiovascular Safety in Ketamine Use for Treatment Resistant Depression
Szarmach, J., Cubała, W. J., Włodarczyk, A., & Gałuszko‐Węgielnik, M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s273287 · Cited by 18
Chu, Q., Zhu, K., Bai, Y., Shang, H., Zhang, D., Zhao, M., Zheng, P., & Jin, X. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2021.735569 · Cited by 18
Craving and addictive potential of esketamine as side effects?
Orsolini, L., Salvi, V., & Volpe, U. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2071422 · Cited by 18
Marchi, M., Magarini, F. M., Galli, G., Mordenti, F., Travascio, A., Uberti, D., Micheli, E. D., Pingani, L., Ferrari, S., & Galeazzi, G. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1011103 · Cited by 18
Pompili, M., Sarli, G., Erbuto, D., Manfredi, G., & Comparelli, A. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000455 · Cited by 19
Huang, C., Hu, L., Wu, L., Geng, F., Wong, G. T. C., Zhang, Y., Reif, A., Bao, Y., Xue, Q., & Lü, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03320-6 · Cited by 17
Liu, Y., & Kou, Z. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100610 · Cited by 17
New Medications for Neuropsychiatric Disorders
Reddy, H. M., Poole, J. S., Maguire, G. A., & Stahl, S. M. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.008 · Cited by 17
Developments in the discovery and design of intranasal antidepressants
Panek, M., Kawalec, P., Pilc, A., & Lasoń, W. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1776697 · Cited by 17
Glutamatergic dysregulation in mood disorders: opportunities for the discovery of novel drug targets
Panek, M., Kawalec, P., Malinowska‐Lipień, I., Brzostek, T., & Pilc, A. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1836160 · Cited by 17
Teeple, A., Zhdanava, M., Pilon, D., Caron‐Lapointe, G., Lefèbvre, P., & Joshi, K. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2239045 · Cited by 17
Siebert, M., Gaba, J. F., Renault, A., Laviolle, B., Locher, C., Moher, D., & Naudet, F. (2022) · BMC Medicine · doi:10.1186/s12916-022-02377-2 · Cited by 17
Guo, H., Tang, L., He, M., Tang, W., Liu, J., Wu, S., Yuan, S., Wang, J., & Tang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1681060 · Cited by 16
Benefits and risks of esketamine nasal spray continuation in treatment-resistant depression
Price, M. Z., & Price, R. L. (2024) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2024.100104 · Cited by 16
Morrison, R. L., Singh, J. B., Daly, E., Fedgchin, M. M., Ochs-Ross, R., Karcher, K., Lane, R., Cooper, K. L., Sanacora, G., Maruff, P. T., et al. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae046 · Cited by 16
Self-citationMa, X., Xue, S., Ma, H., Saeed, S., Zhang, Y., Meng, Y., Chen, H., Yu, H., Wang, H., Hu, S., et al. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2024.12.062 · Cited by 16
Somatic Comorbidities and Cardiovascular Safety in Ketamine Use for Treatment-Resistant Depression
Szarmach, J., Cubała, W. J., Włodarczyk, A., & Gałuszko‐Węgielnik, M. (2021) · Medicina · doi:10.3390/medicina57030274 · Cited by 16
“Novel Psychopharmacology for Depressive Disorders”
Fornaro, M., Berardis, D. D., Anastasia, A., & Fusco, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_22 · Cited by 16
Yrondi, A., Bennabi, D., Haffen, É., Quélard, D., Samalin, L., Maruani, J., Allauze, E., Pierre, D., Bougerol, T., Camus, V., et al. (2020) · Brain Sciences · doi:10.3390/brainsci10120962 · Cited by 16
Metadata
- Authors
- Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., Ravindran, A., Gaillard, R., Ameele, H. V. D., Preskorn, S., Manji, H., Hough, D., Drevets, W. C., & Singh, J. B.
- Affiliations
- Janssen Research and Development, Department of Neuroscience, Titusville, New Jersey
- The University of Texas Southwestern Medical Center (US)
- Janssen Research and Development, Clinical Biostatistics, Titusville, New Jersey
- University of Ottawa (CA)
- Clinical Trials Network and Institute, Massachusetts General Hospital, Boston, Massachusetts
- Medical Research Network (US)
- University of Toronto (CA)
- Centre Hospitalier Sainte Anne, Service Hospitalo-Universitaire, Paris, France
- AZ Sint-Jan (BE)
- University of Kansas (US)
- Janssen Research and Development, Department of Neuroscience, San Diego, California
- Corresponding author
- Fedgchin, Maggie
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-07-10
- Volume
- 22
- Issue
- 10
- Pages
- 616-630
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC6822141
- OpenAlex
- W2961020354
- Semantic Scholar
- 3739b211f156e1c4836c25e44222f6497502cdd7
- Cited by
- 606
- References
- 32
- Citations by year
- 2026: 49 · 2025: 73 · 2024: 58 · 2023: 59 · 2022: 72 · 2021: 62 · 2020: 222 · 2019: 10
- FWCI
- 56.67
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- esketamine, nasal spray, treatment-resistant depression, antidepressant combination therapy, rapid-acting antidepressants, antidepressant non-response, depression remission, adverse events, dissociation, nausea
- MeSH terms
- Duloxetine Hydrochloride, Venlafaxine Hydrochloride, Administration, Intranasal, Administration, Oral, Adolescent, Adult, Antidepressive Agents, Delayed-Action Preparations, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Ketamine, Male, Middle Aged, Citalopram, Treatment Outcome, Sertraline, Young Adult, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.